Prevent Cancer Preclinical Drug Development Program Tender, USA - 73105509

Procurement Summary

Country : USA

Summary : Prevent Cancer Preclinical Drug Development Program

Deadline : 28 Oct 2022

Other Information

Notice Type : Tender

TOT Ref.No.: 73105509

Document Ref. No. :

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Description

Pre-Solicitation Notice of Intent to Sole Source

PREVENT Cancer Preclinical Drug Development Program:

This is a sole source synopsis for the Indefinite Delivery Indefinite Quantity (IDIQ) contracts within the PREVENT Cancer Preclinical Drug Development Program, herein referred to as the PREVENT 2019 IDIQ Contracts. The current IDIQ consists of three pools, Preclinical Efficacy and Intermediate Endpoint Biomarker Pool (herein referred to as the Efficacy Pool), Toxicology and Pharmacology Testing Pool (herein referred to as the Tox/Pharm Pool), and Biopharmaceutical Product Development and Manufacturing Pool (herein referred to as the CGMP Pool). This announcement constitutes a synopsis for this requirement, is issued for notification purposes only and is not a request for competitive proposals.

The National Cancer Institute (NCI) plans to issue modifications to increase the shared programmatic ceilings on each of the PREVENT 2019 IDIQ Contracts to continue to advance the preclinical development of cancer-preventative interventions and intermediate biomarkers and to support/enable their clinical translation. This continued Efficacy work is accomplished by conducting preclinical animal studies for cancer preventive efficacy evaluation, employing detailed pharmacological and/or immunological studies, determining pharmacodynamic (PD) and/or immunodynamic (ID) effects of test agents, and correlating pharmacokinetic and/or immunologic biomarker profile(s) with the effectiveness of test agents. This continued Tox/Pharm work is accomplished through studies in genotoxicity testing, general toxicology in experimental animals, reproductive toxicology studies in rodents and rabbits and other specialized studies. This continued cGMP work is accomplished through product development planning and evaluation, analytical assay development and product characterization, process development and related activities and cGMP manufacture, related activities and do...
Active Contract Opportunity
Notice ID :
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office : NIH NCI
General Information
Contract Opportunity Type: Special Notice (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Oct 13, 2022 08:06 am EDT
Original Response Date: Oct 28, 2022 04:00 pm EDT
Inactive Policy: 15 days after response date
Original Inactive Date:
Initiative: None

Classification
Original Set Aside:
Product Service Code: AN12 - Health R&D Services; Health care services; Applied Research
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance:

Documents

 Tender Notice

Statements-of-Work.pdf